BMRN BioMarin Pharmaceutical Inc.
Stock · NasdaqGS · United States · Healthcare · US09061G1013
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by BioMarin Pharmaceutical Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
56.03 USD
-0.16%
52-week range
49.26 – 70.98
Dividend yield—
Market cap10.9B
NowoTrade score
54 Grade A
Price history
Daily prices in USD.
Updated 06 Nov 2026 21:09. Information, not advice.
Results
Next results
22 Feb 2027
in 107 days · 16:00 · estimate 0.94
Last results
0.23 vs -0.11 estimated
02 Nov 2026 · Beat +304.8%
Beat the estimate
9 of 12
3 missed · 0 in line · 2 beats in a row
Average surprise
+34.8%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 22 Feb 2027 16:00 | 0.94 | — | — | Upcoming |
| 02 Nov 2026 16:00 | -0.11 | 0.23 | +304.8% | Beat |
| 06 Aug 2026 16:00 | 0.95 | 1.20 | +25.8% | Beat |
| 04 May 2026 16:00 | 0.91 | 0.76 | -16.9% | Miss |
| 23 Feb 2026 16:00 | 0.56 | 0.46 | -17.9% | Miss |
| 27 Oct 2025 16:00 | 0.34 | 0.12 | -64.3% | Miss |
| 04 Aug 2025 16:00 | 1.03 | 1.44 | +39.4% | Beat |
| 01 May 2025 16:00 | 0.95 | 1.13 | +18.6% | Beat |
| 19 Feb 2025 16:00 | 0.74 | 0.92 | +24.6% | Beat |
| 29 Oct 2024 16:00 | 0.79 | 0.91 | +14.7% | Beat |
| 05 Aug 2024 16:00 | 0.60 | 0.96 | +61.0% | Beat |
| 24 Apr 2024 16:00 | 0.60 | 0.71 | +18.3% | Beat |
| 22 Feb 2024 16:00 | 0.45 | 0.49 | +9.5% | Beat |
| 01 Nov 2023 16:00 | 0.48 | 0.46 | -4.7% | Miss |
| 31 Jul 2023 16:00 | 0.47 | 0.54 | +14.3% | Beat |
| 26 Apr 2023 16:00 | 0.40 | 0.60 | +48.5% | Beat |
| 27 Feb 2023 16:00 | 0.39 | 0.36 | -6.3% | Miss |
| 26 Oct 2022 16:00 | 0.43 | 0.45 | +4.9% | Beat |
| 03 Aug 2022 16:00 | 0.53 | 0.58 | +9.5% | Beat |
| 27 Apr 2022 16:00 | 0.46 | 0.54 | +18.8% | Beat |
| 23 Feb 2022 16:00 | -0.01 | 0.04 | +435.4% | Beat |
| 27 Oct 2021 16:00 | 0.09 | 0.18 | +105.0% | Beat |
| 28 Jul 2021 16:00 | 0.25 | 0.53 | +107.6% | Beat |
| 29 Apr 2021 16:00 | 0.30 | 0.57 | +86.8% | Beat |
| 25 Feb 2021 16:00 | 0.18 | 0.21 | +16.0% | Beat |
| 05 Nov 2020 16:00 | 0.26 | 0.50 | +95.7% | Beat |
| 04 Aug 2020 16:00 | 0.19 | 0.32 | +71.0% | Beat |
| 29 Apr 2020 17:00 | 0.33 | 0.62 | +86.3% | Beat |
| 26 Feb 2020 16:00 | 0.24 | 0.25 | +5.6% | Beat |
| 23 Oct 2019 16:00 | 0.34 | 0.42 | +23.2% | Beat |
| 01 Aug 2019 16:00 | 0.19 | 0.10 | -50.5% | Miss |
| 25 Apr 2019 16:00 | 0.10 | 0.14 | +35.7% | Beat |
| 21 Feb 2019 16:00 | 0.12 | -0.06 | -152.4% | Miss |
| 25 Oct 2018 16:00 | 0.15 | 0.34 | +128.5% | Beat |
| 02 Aug 2018 16:00 | 0.15 | 0.11 | -24.9% | Miss |
| 25 Apr 2018 16:00 | 0.13 | 0.12 | -3.7% | Miss |
| 22 Feb 2018 16:00 | 0.04 | 0.03 | -23.0% | Miss |
| 26 Oct 2017 16:00 | 0.08 | 0.04 | -40.8% | Miss |
| 02 Aug 2017 16:00 | 0.08 | 0.15 | +82.5% | Beat |
| 04 May 2017 16:00 | -0.01 | 0.20 | +1,766.7% | Beat |
| 23 Feb 2017 16:00 | -0.07 | -0.16 | -109.3% | Miss |
| 27 Oct 2016 16:00 | -0.08 | 0.02 | +121.3% | Beat |
| 04 Aug 2016 16:00 | -0.11 | 0.10 | +191.0% | Beat |
| 28 Apr 2016 16:00 | -0.28 | -0.16 | +44.0% | Beat |
| 25 Feb 2016 16:00 | -0.12 | -0.43 | -266.1% | Miss |
| 29 Oct 2015 16:00 | -0.58 | -0.56 | +3.4% | Beat |
| 03 Aug 2015 16:00 | -0.66 | -0.34 | +47.8% | Beat |
| 30 Apr 2015 16:00 | -0.56 | -0.39 | +30.4% | Beat |
| 25 Feb 2015 16:00 | -0.55 | -0.47 | +14.7% | Beat |
| 23 Oct 2014 16:00 | -0.24 | -0.32 | -29.4% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 3.2B | +12.9% | 348.9M | 10.8% | 1.80 | -18.6% | 717M |
| 2024 | 2.9B | +18.0% | 426.9M | 15.0% | 2.21 | +154.0% | 475.4M |
| 2023 | 2.4B | +15.4% | 167.6M | 6.9% | 0.87 | +16.0% | 51.6M |
| 2022 | 2.1B | — | 141.6M | 6.8% | 0.75 | — | 44.4M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 17 Jun 2024 | 83.06 | 85.58 | 83.06 | 85.02 | +1.81% | 2,627,400 | |
| 14 Jun 2024 | 83.57 | 84.75 | 83.07 | 83.51 | -0.87% | 2,476,400 | |
| 13 Jun 2024 | 84.40 | 84.89 | 83.37 | 84.24 | -0.37% | 3,944,300 | |
| 12 Jun 2024 | 84.04 | 85.30 | 83.53 | 84.55 | +0.81% | 3,412,700 | |
| 11 Jun 2024 | 82.20 | 84.15 | 82.19 | 83.87 | +1.12% | 3,214,900 | |
| 10 Jun 2024 | 84.48 | 85.51 | 82.85 | 82.94 | +2.79% | 7,450,400 | |
| 07 Jun 2024 | 81.00 | 81.47 | 80.31 | 80.69 | -0.20% | 1,495,800 | |
| 06 Jun 2024 | 79.67 | 81.15 | 78.95 | 80.85 | +1.48% | 1,966,000 | |
| 05 Jun 2024 | 79.02 | 79.81 | 77.75 | 79.67 | +0.73% | 1,949,800 | |
| 04 Jun 2024 | 76.80 | 79.63 | 75.89 | 79.09 | +3.51% | 3,772,100 | |
| 03 Jun 2024 | 75.75 | 77.75 | 75.40 | 76.41 | +1.79% | 2,466,500 | |
| 31 May 2024 | 74.54 | 75.33 | 74.17 | 75.07 | +0.79% | 2,545,800 | |
| 30 May 2024 | 75.19 | 75.29 | 73.68 | 74.48 | -0.77% | 2,074,000 | |
| 29 May 2024 | 74.11 | 75.33 | 73.69 | 75.06 | +0.85% | 2,760,000 | |
| 28 May 2024 | 75.69 | 75.78 | 74.09 | 74.43 | -1.44% | 2,864,100 | |
| 24 May 2024 | 75.77 | 75.96 | 75.12 | 75.52 | -0.50% | 2,028,900 | |
| 23 May 2024 | 76.17 | 76.17 | 75.03 | 75.90 | -0.72% | 2,859,300 | |
| 22 May 2024 | 76.77 | 78.19 | 76.38 | 76.45 | -1.15% | 2,746,500 | |
| 21 May 2024 | 76.72 | 77.61 | 76.40 | 77.34 | +0.38% | 1,837,600 | |
| 20 May 2024 | 77.52 | 77.58 | 76.25 | 77.05 | -0.66% | 1,731,200 | |
| 17 May 2024 | 76.24 | 78.03 | 76.14 | 77.56 | +0.77% | 3,433,400 | |
| 16 May 2024 | 80.18 | 80.66 | 76.52 | 76.97 | -4.27% | 3,858,000 | |
| 15 May 2024 | 80.12 | 80.96 | 79.96 | 80.40 | +0.94% | 2,124,300 | |
| 14 May 2024 | 80.74 | 80.74 | 79.52 | 79.65 | -1.06% | 1,530,800 | |
| 13 May 2024 | 81.24 | 81.57 | 80.37 | 80.50 | -0.65% | 1,291,800 |
Page 25 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- BioMarin Pharmaceutical Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 05 Nov 2026 02:57
- JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86 (opens in a new tab) Benzinga · 04 Nov 2026 16:11
- BioMarin to Participate in Upcoming Investor Conferences (opens in a new tab) 04 Nov 2026 14:00
- BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions (opens in a new tab) SeekingAlpha · 04 Nov 2026 11:33
- BioMarin Pharmaceutical Inc (BMRN) Q3 2026 Earnings Call Highlights: First $1 Billion Revenue ... (opens in a new tab) GuruFocus.com · 04 Nov 2026 03:02
- BioMarin Pharmaceutical Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 03 Nov 2026 13:30
- Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119 (opens in a new tab) Benzinga · 03 Nov 2026 13:23
- Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94 (opens in a new tab) Benzinga · 03 Nov 2026 13:11
- HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target (opens in a new tab) Benzinga · 03 Nov 2026 13:05
- BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs (opens in a new tab) InvestorsHub · 03 Nov 2026 11:19
- RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $60 (opens in a new tab) Benzinga · 03 Nov 2026 10:55
- Stifel Maintains Hold on BioMarin Pharmaceutical, Lowers Price Target to $66 (opens in a new tab) Benzinga · 03 Nov 2026 09:00
- BioMarin (BMRN) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 03 Nov 2026 04:43
- BioMarin Pharmaceutical Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 03 Nov 2026 02:14
- BioMarin Pharmaceutical (BMRN) Could Be 21% Undervalued On Mixed Q3 Guidance Cut (opens in a new tab) Simply Wall St. · 03 Nov 2026 02:09
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 56.12 USD
- Market cap
- 10.9B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 4.4 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 11.7 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.5 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Heavy debt: net debt is 4.0× EBITDA
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 8.84× | Good | 14.98× |
| Price / book | 1.73× | Fair | 3.87× |
| Price / sales | 2.97× | Fair | 3.42× |
| EV / EBITDA | 16.75× | Weak | 13.22× |
| Free cash flow yield | -0.1% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 53.2% | Good | 59.2% |
| Operating margin | 26.6% | Good | 7.8% |
| Net margin | -0.5% | Weak | 3.4% |
| Return on equity | -0.3% | Weak | 5.9% |
| Return on assets | 3.9% | Fair | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 15.4% | Good | 10.8% |
| EPS growth / year | 33.9% | Good | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.67× | Good | 0.46× |
| Net debt / EBITDA | 4.04× | Weak | 1.48× |
| Interest cover | 37.57× | Good | 3.26× |
| Current ratio | 2.44× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow BMRN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.